Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer

Gu, Xiaobin; Gao, Xianshu; Cui, Ming; Xie, Mu; Peng, Chuan; Bai, Yun; Guo, Wei; Han, Linjun; Gu, Xiaodong; Wang, Xiong

doi:10.18632/oncotarget.10490

Cited by 58 publications

(63 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results regarding breast cancer were in line with results of studies on other cancer forms [31, 33, 36]. We noted that breast cancer was investigated merely as a small proportion of all cancer types in previous meta-analyses with at most two primary studies included [34, 35].…”

Section: Discussionsupporting

confidence: 89%

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer

et al. 2016

View full text Add to dashboard Cite

Platelet-lymphocyte ratio (PLR) is a hematological parameter which is investigated as a biomarker for prognosis in patients with breast cancer. Due to the controversial results from previous studies, we performed a meta-analysis. Databases of PubMed, Embase and Web of Science were searched to identify eligible studies. STATA version 12.0 was used for statistical analysis. Seven studies with 3,741 patients were ultimately included in this meta-analysis. High PLR was associated with poor overall survival (OS) (HR = 1.55, 95% CI = 1.07–2.25, p = 0.022) and disease-free survival (DFS) (HR = 1.73, 95% CI = 1.3-2.3, p < 0.001) in breast cancer patients. Subgroup analyses disclosed that elevated PLR could predict worse OS in Asian populations and poor DFS in both Asian and non-Asian patients. In addition, PLR remains a significant prognostic marker for OS in patients receiving systemic treatment (HR = 1.78, 95% CI = 1.06–2.99, p = 0.03) and patients receiving chemotherapy (HR = 2.82, 95% CI = 1.09–7.26, p = 0.032). High PLR also indicates poor DFS in patients who receive chemotherapy (HR = 2.6, 95% CI = 1.47–4.61, p = 0.001), surgery (HR = 1.8, 95% CI = 1.12–2.89, p = 0.016) and systemic treatment (HR = 2.03, 95% CI = 1.03–4.01, p = 0.042). Moreover, PLR was also in association with HER-2 positivity (OR = 1.48, 95% CI = 1.2–1.83, p < 0.001). In conclusion, this meta-analysis revealed that PLR could serve as an indicator of poor prognosis in patients with breast cancer.

show abstract

Section: Discussionsupporting

confidence: 89%

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…NLR, PLR, and C-reactive protein (CRP) are often used as hematological markers of systemic inflammation to reflect the balance between the host inflammatory response and immune response [39]. The association between inflammation markers (NLR, PLR, CRP) and cancer has already been observed in various types of gastrointestinal malignancies, including esophageal cancer, gastric cancer, colorectal cancer, and pancreatic cancer [38,[40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis

Feng

Cao

et al. 2020

PLoS ONE

View full text Add to dashboard Cite

ObjectivesTo investigate the association between inflammatory indices and clinical outcomes of hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE) by performing meta-analysis. MethodsA systematic literature search for relevant studies published up to August 2019 was performed by using PubMed, Web of Science, EMBASE, China National Knowledge Internet (CNKI) and Wanfang databases. Pooled hazard ratios (HR) or odds ratio (OR) and 95% confidence intervals (95% CI) were calculated. ResultsA total of 5280 patients from 22 studies were finally enrolled in the meta-analysis. The results demonstrated that elevated preoperative NLR, PLR, and CRP was associated with poor OS in HCC patients treated by TACE (HR = 1.81, P<0.00001; HR = 1.56, P = 0.007; HR = 1.45, P<0.00001, respectively). In addition, high NLR was significantly correlated with the presence of tumor vascular invasion (OR = 1.49, P = 0.002). Elevated PLR tended to be correlated with higher incidence of tumor size>3 cm (OR = 2.42, P = 0.005). ConclusionsElevated preoperative NLR, PLR, and CRP are associated with poor prognosis in HCC patients treated with TACE. These inflammatory indices may be convenient, accessible, PLOS ONE

show abstract

“…Elevated PLR showed association with lymph node metastasis with the relevant odds ratio of 1.50 (OR 1.24-1.82) as reported by Xu et al [85]. In another meta-analysis comprising 14 cohorts and 6280 cases, elevated PLR also was significantly associated with lymph node metastases [86]. However, in a multicentre study of 245 gastric cancer patients, PLR was not associated with N [61].…”

Section: Metastases In Regional Lymph Nodes: Nmentioning

confidence: 61%

“…In another meta-analysis comprising 14 cohorts and 6280 cases, PLR was associated with poor overall survival (HR 1.3; 95% CI 1.1-1.5) but not with worse cancer-free survival (HR 1.6; 95% = CI 0.9-2.9). High PLR predicted poor survival in Caucasians, patients receiving chemotherapy and patients at advanced stage [86].…”

Section: Plr and Survival: Prognostic Implicationsmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Inflammatory Reaction in Gastric Cancer: Biology and Practical Implications of Neutrophil to Lymphocyte Ratio, Glasgow Prognostic Score and Related Parameters

Štrumfa¹,

Bogdanova²,

Kalva³

et al. 2017

Gastric Cancer

View full text Add to dashboard Cite

Gastric cancer induces systemic inflammatory reaction (SIR) manifesting with changes in counts of white blood cell fractions and concentrations of acute phase proteins, clotting factors and albumins. Thus, protein-based scores or blood cell ratios (neutrophil to lymphocyte ratio (NLR); platelet to lymphocyte ratio (PLR)) are used to evaluate SIR. SIR tests are biologically justified by multiple clinically important and fascinating events including bone marrow activation, development of immune-suppressing immature myeloid cells, generation of pre-metastatic niches and neutrophil extracellular trap formation from externalised DNA network in bidirectional association with platelet activation. Despite biological complexity, clinical SIR assessment is widely available, patient-friendly and economically feasible. Here we present concise review on NLR, PLR, Glasgow prognostic score and fibrinogen -parameters that have prognostic role regarding overall, cancer-free and cancer-specific survival in early and advanced cases. Tumour burden can be predicted helping in preoperative detection of serosal or lymph node involvement. Practical consequences abound, including selection of surgical approach in respect to tumour burden, adjustments in treatment intensity by prognosis or evaluation of chemotherapy response. The chapter also scrutinises main controversies including different cut-off levels. Future developments should include elaboration of complex scores as described here. SIR parameters should be wisely incorporated in patients' treatment.

show abstract

Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer

Cited by 58 publications

References 43 publications

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer

Platelet-lymphocyte ratio acts as an indicator of poor prognosis in patients with breast cancer

Prognostic significance of inflammatory indices in hepatocellular carcinoma treated with transarterial chemoembolization: A systematic review and meta-analysis

Systemic Inflammatory Reaction in Gastric Cancer: Biology and Practical Implications of Neutrophil to Lymphocyte Ratio, Glasgow Prognostic Score and Related Parameters

Contact Info

Product

Resources

About